Trends and developments in liposome drug delivery systems

被引:708
作者
Lian, T [1 ]
Ho, RJY [1 ]
机构
[1] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA
关键词
D O I
10.1002/jps.1023
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Since the discovery of liposomes or lipid vesicles derived from self-forming enclosed lipid bilayers upon hydration, liposome drug delivery systems have played a significant role in formulation of potent drugs to improve therapeutics. Currently, most of these liposome formulations are designed to reduce toxicity and to some extent increase accumulation at the target site(s) in a number of clinical applications. The current pharmaceutical preparations of liposome-based therapeutics stem from our understanding of lipid-drug interactions and liposome disposition mechanisms including the inhibition of rapid clearance of liposomes by controlling size, charge, and surface hydration. The insight gained from clinical use of liposome drug delivery systems can now be integrated to design liposomes targeted to tissues and cells with or without expression of target recognition molecules on liposome membranes. Enhanced safety and heightened efficacy have been achieved for a wide range of drug classes, including antitumor agents, antivirals, antifungals, antimicrobials, vaccines, and gene therapeutics. Additional refinements of biomembrane sensors and liposome delivery systems that are effective in the presence of other membrane-bound proteins in vivo may permit selective delivery of therapeutic compounds to selected intracellular target areas. (C) 2001 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 90:667-680, 2001.
引用
收藏
页码:667 / 680
页数:14
相关论文
共 91 条
[21]   Clinical applications of angiogenic growth factors and their inhibitors [J].
Ferrara, N ;
Alitalo, K .
NATURE MEDICINE, 1999, 5 (12) :1359-1364
[22]   Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: In vitro studies [J].
Gabizon, A ;
Horowitz, AT ;
Goren, D ;
Tzemach, D ;
Mandelbaum-Shavit, F ;
Qazen, MM ;
Zalipsky, S .
BIOCONJUGATE CHEMISTRY, 1999, 10 (02) :289-298
[23]  
Gabizon AA, 1998, MEDICAL APPLICATIONS OF LIPOSOMES, P625, DOI 10.1016/B978-044482917-7/50034-X
[24]   LIPOSOME CIRCULATION TIME AND TUMOR TARGETING - IMPLICATIONS FOR CANCER-CHEMOTHERAPY [J].
GABIZON, AA .
ADVANCED DRUG DELIVERY REVIEWS, 1995, 16 (2-3) :285-294
[25]  
Gluck R, 1995, Pharm Biotechnol, V6, P325
[26]   Targeting of stealth liposomes to erbB-2 (Her/2) receptor: In vitro and in vivo studies [J].
Goren, D ;
Horowitz, AT ;
Zalipsky, S ;
Woodle, MC ;
Yarden, Y ;
Gabizon, A .
BRITISH JOURNAL OF CANCER, 1996, 74 (11) :1749-1756
[27]   ATTACHMENT OF ANTIBODIES TO STERICALLY STABILIZED LIPOSOMES - EVALUATION, COMPARISON AND OPTIMIZATION OF COUPLING PROCEDURES [J].
HANSEN, CB ;
KAO, GY ;
MOASE, EH ;
ZALIPSKY, S ;
ALLEN, TM .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1995, 1239 (02) :133-144
[28]   CONJUGATION OF CHOLERA-TOXIN OR ITS B-SUBUNIT TO LIPOSOMES FOR TARGETED DELIVERY OF ANTIGENS [J].
HAROKOPAKIS, E ;
CHILDERS, NK ;
MICHALEK, SM ;
ZHANG, SS ;
TOMASI, M .
JOURNAL OF IMMUNOLOGICAL METHODS, 1995, 185 (01) :31-42
[29]   Transport of colloidal particles in lymphatics and vasculature after subcutaneous injection [J].
Higuchi, M ;
Fokin, A ;
Masters, TN ;
Robicsek, F ;
Schmid-Schönbein, GW .
JOURNAL OF APPLIED PHYSIOLOGY, 1999, 86 (04) :1381-1387
[30]   TARGET-SENSITIVE IMMUNOLIPOSOMES - PREPARATION AND CHARACTERIZATION [J].
HO, RJY ;
ROUSE, BT ;
HUANG, L .
BIOCHEMISTRY, 1986, 25 (19) :5500-5506